Sparking a Movement
Dova is committed to identifying, acquiring, developing and commercializing drug candidates — and doing so in some unexpected ways. As we target rare diseases where the unmet need is high, we’re also looking beyond to ensure our drug candidates help as many as patients as possible.
Our Flashpoint. And Beyond…
Our passionate approach to improving people’s lives is apparent with our current lead compound, avatrombopag, a second generation thrombopoetin receptor agonist (TPO-RA) which is being evaluated for use in the treatment of liver disease patients with thrombocytopenia who are scheduled to undergo a medical procedure. In addition, we are also exploring the use of avatrombopag, which has not been approved by the U.S. Food & Drug Administration or other regulatory authorities, for patients with thrombocytopenia undergoing more invasive surgical procedures (e.g. joint replacement) as well as cancer patients who develop thrombocytopenia when undergoing chemotherapy.
- Medical procedure refers to a non-emergent, minimally to moderately invasive medical procedure
- Surgery includes spectrum of minimally invasive to highly invasive medical procedures. For highly invasive surgeries such as vascular, cardiac, brain or spine surgeries, many medical professional associations’ guidelines recommend that patients have at least 100K platelets / uL